CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 108 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $8,000 | +300.0% | 2,517 | +312.6% | 0.00% | – |
| Q3 2021 | $2,000 | -71.4% | 610 | -62.5% | 0.00% | – |
| Q2 2021 | $7,000 | -87.7% | 1,626 | -83.5% | 0.00% | -100.0% |
| Q4 2020 | $57,000 | +58.3% | 9,868 | -5.1% | 0.00% | -25.0% |
| Q2 2020 | $36,000 | +3500.0% | 10,402 | +1070.1% | 0.00% | – |
| Q1 2020 | $1,000 | -80.0% | 889 | -62.3% | 0.00% | -100.0% |
| Q4 2019 | $5,000 | +400.0% | 2,361 | +781.0% | 0.00% | – |
| Q3 2019 | $1,000 | -98.0% | 268 | -93.0% | 0.00% | -100.0% |
| Q2 2018 | $51,000 | – | 3,835 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |